Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration

Autoři	KAYSER S. ELLIOTT M. A. LUSKIN M. BRUNNER A. M. KRAMER M. RÁČIL Zdeněk NOVÁKOVÁ Zuzana CETKOVSKY P. NOVAK J. STOELZEL F. THIEDE C. MULLER-TIDOW C. PLATZBECKER U. ROLLIG C. SCHLENK R. F. LEVIS M. J.
Rok publikování	2019
Druh	Konferenční abstrakty
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Popis	Core binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22) and is associated with a favorable outcome, particularly if treated with repetitive cycles of high-dose cytarabine as post-remission therapy. Long-time 10-year overall survival (OS) rate was reported of 58% in FLT3-ITD negative patients (pts; Allen et al. Leukemia 2013). Nevertheless, 30-40% CBF-AML pts experience relapse. FLT3-ITD mutations occur in roughly 5-10% of adult CBF-AML. However, their prognostic relevance is still controversial.